MORI TOSHIO,모리, 토시오,DEGAWA YOUKO,데가와, 요우코,SHIBANUMA KIYOSHI,시바누마, 기요시
申请号：
KR1020120041440
公开号：
KR1020130027075A
申请日:
2012.04.20
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: A medicine which promotes the secretion of GLP-1 and restrains the secretion of GIP is provided to promoting the desired GLP-1 while restraining the secretion of GIP which is not desirable for the treatment of the impaired glucose tolerance and the prevention of diabetes. CONSTITUTION: A medicine is for promoting the secretion of GLP-1(glucagon like peptide 1) and restraining the secretion of GIP(Glucose dependent insulin secretion stimulation polypeptide). The medicine contains the none-competitive type inhibitor of the sucroclastic enzyme as an effective ingredient, and the none-competitive type inhibiter is the L-arabinose, D-xylose, and/or D-tagatose. The combination ratio of the non-competitive type inhibitor is 4.5-99 wt % in case of L-arabinose and D-xylose and 25-99wt% in case of D-tagatose. The medicine is taken with sucrose or food containing sucrose, and is taken within 90 minutes before the intake of the sucrose or the food. The food containing sucrose is Japanese style snacks, western style snacks, dairy products, drink, or beverage. [Reference numerals] (AA) Active GLP-1； (BB) Sucrose； (CC) Sucrose + arabinose； (DD) Arabinose； (EE) Time(minutes)GIP 의 분비를 완전히 억제하면서도 GLP-1 의 분비를 촉진시킬 수 있으며, 또한 안전성이 우수한 인크레틴 호르몬 관련약을 제공한다. L-아라비노스, D-크실로스, 및 D-타가토스 등의 자당 분해효소의 비-길항형 저해제를 유효성분으로서 함유하는 것을 특징으로 하는 GLP-1(글루카곤형 펩티드 1)의 분비를 촉진시키고 또한 GIP(글루코스 의존성 인슐린 분비 자극 폴리펩티드)의 분비를 억제하는 약제.
